Individuals with chronic hepatitis B virus (HBV) infection, (i.e., HBsAg-positive), and even those with resolved infection (HBsAg-negative/anti-HBc-positive) are at risk of HBV reactivation when receiving chemotherapy1, especially those treated with rituximab-containing regimens2. This evidence concerns the gene KRT88P and infection.